Core Insights - Opus Genetics, Inc. has approved equity awards for two new employees as part of its 2021 Inducement Plan, effective March 13, 2025 [1] - The equity awards consist of options to purchase a total of 205,742 shares at an exercise price of $0.93 per share, with a four-year vesting schedule [2] - Opus Genetics is focused on developing therapies for inherited retinal diseases (IRDs) and other ophthalmic disorders, with a pipeline that includes gene therapies and other investigational treatments [3] Group 1 - The independent Board of Directors approved equity awards as a material inducement for new hires [1] - The options granted will vest over four years, with 25% vesting after one year and the remainder in monthly or quarterly installments [2] - The company is developing AAV-based gene therapies targeting specific genetic mutations associated with various retinal diseases [3] Group 2 - The most advanced program targets mutations in the LCA5 gene, currently in a Phase 1/2 trial with promising early results [3] - Other investigational products include BEST1 gene therapy and Phentolamine Ophthalmic Solution 0.75%, which is in Phase 3 trials for presbyopia [3] - The company has reached an agreement with the FDA for a Phase 3 trial of oral APX3330 for diabetic retinopathy treatment [3]
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)